Cost-effectiveness of telemonitoring and self-monitoring of blood pressure for antihypertensive titration in primary care (TASMINH4) by Monahan, Mark et al.
 
 
University of Birmingham
Cost-effectiveness of telemonitoring and self-
monitoring of blood pressure for antihypertensive
titration in primary care (TASMINH4)
Monahan, Mark; Jowett, Sue; Nickless, Alecia; Franssen, Marloes; Grant, Sabrina;
Greenfield, Sheila; Hobbs, F. D. Richard; Hodgkinson, James; Mant, Jonathan; McManus,
Richard J.
DOI:
10.1161/HYPERTENSIONAHA.118.12415
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Monahan, M, Jowett, S, Nickless, A, Franssen, M, Grant, S, Greenfield, S, Hobbs, FDR, Hodgkinson, J, Mant, J
& McManus, RJ 2019, 'Cost-effectiveness of telemonitoring and self-monitoring of blood pressure for
antihypertensive titration in primary care (TASMINH4)', Hypertension, vol. 73, no. 6, pp. 1231-1239.
https://doi.org/10.1161/HYPERTENSIONAHA.118.12415
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4),
Mark Monahan et al, Originally published 1 Jun 2019, https://doi.org/10.1161/HYPERTENSIONAHA.118.12415Hypertension.
2019;73:1231–1239
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
1231
Hypertension is the foremost risk factor for cardiovascular disease and a significant contributor to mortality and 
morbidity worldwide.1 Blood pressure (BP) reduction using 
antihypertensive drugs reduces cardiovascular disease risk for 
hypertensive patients but many patients do not achieve op-
timal BP control.2,3 Self-management of treated hypertension, 
where the patient self-monitors their BP and titrates their own 
antihypertensive medication, has been shown to reduce BP 
and be cost-effective compared with routine care.4,5 However, 
until recently, the evidence for the use of self-monitoring to 
titrate antihypertensive medication by physicians was equiv-
ocal.6,7 The telemonitoring and/or self-monitoring of blood 
pressure in hypertension (TASMINH4) trial provided new 
evidence that physician titration using patient self-monitoring 
led to lower BP and that including telemonitoring led to lower 
BP quicker than self-monitoring alone.8 However, it remains 
unclear whether self-monitoring is cost-effective and whether 
the additional benefits from telemonitoring are sufficient to 
justify its use over and above self-monitoring alone on cost-ef-
fectiveness grounds.
The aim of this study was to estimate the long-term 
cost-effectiveness of general practitioner (GP) titration of anti-
hypertensive medication using self-monitored BP to make hy-
pertension treatment decisions in primary care, with or without 
telemonitoring, compared with usual care, from a National 
Health Service (NHS)/Personal Social Services perspective.
Methods
Requests for the data in this article should be addressed to the corre-
sponding author.
Full details of the TASMINH4 trial have been published else-
where.8,9 Briefly, this was a randomized controlled trial assessing the 
efficacy of using self-monitored BP, with or without telemonitoring, 
to guide antihypertensive titration in primary care. Eligible patients 
were hypertensive, aged >35 years, with a clinic BP >140/90 mm Hg 
and willing to self-monitor their BP. Across 138 GP practices, 1182 
patients were randomized (1:1:1) to antihypertensive titration using 
self-monitoring, telemonitoring, or usual care (clinic BP).
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Abstract—The use of self-monitoring of blood pressure, with or without telemonitoring, to guide therapy decisions by 
physicians for patients with hypertension has been recently demonstrated to reduce blood pressure compared with using 
clinic monitoring (usual care). However, both the cost-effectiveness of these strategies compared with usual care, and 
whether the additional benefit of telemonitoring compared with self-monitoring alone could be considered value for 
money, are unknown. This study assessed the cost-effectiveness of physician titration of antihypertensive medication using 
self-monitored blood pressure, with or without telemonitoring, to make hypertension treatment decisions in primary care 
compared with usual care. A Markov patient-level simulation model was developed taking a UK Health Service/Personal 
Social Services perspective. The model adopted a lifetime time horizon with 6-month time cycles. At a willingness to 
pay of £20 000 per quality-adjusted life year, self-monitoring plus telemonitoring was the most cost-effective strategy 
(£17 424 per quality-adjusted life year gained) compared with usual care or self-monitoring alone (posting the results 
to the physician). However, deterministic sensitivity analysis showed that self-monitoring alone became the most cost-
effective option when changing key assumptions around long-term effectiveness and time horizon. Overall, probabilistic 
sensitivity analysis suggested that self-monitoring regardless of transmission modality was likely to be cost-effective 
compared with usual care (89% probability of cost-effectiveness at £20 000/quality-adjusted life year), with high 
uncertainty as to whether telemonitoring or self-monitoring alone was the most cost-effective option. Self-monitoring in 
clinical practice is cost-effective and likely to lead to reduced cardiovascular mortality and morbidity.  (Hypertension. 
2019;73:1231-1239. DOI: 10.1161/HYPERTENSIONAHA.118.12415.)
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The self-monitoring and telemonitoring interventions are de-
scribed in detail in the section on model comparators. The primary 
outcome for the trial was clinic systolic BP measured by a research 
nurse at 12 months. Cost and resource utilization data were collected 
during the trial through notes review.9 It was not possible to capture 
primary care workload not recorded in the clinical records.
A Markov patient-level simulation was undertaken in TreeAge 
2018 (TreeAge Software, Inc, Williamstown, MA) to model the dif-
ferent strategies. This type of Markov model tracks the costs and 
consequences of individual patients passing through the model, with 
characteristics (taken from TASMINH4 patient-level data) free to 
vary between patients. The model was run over a lifelong (maximum 
of 65 years; minimum trial inclusion criteria was age 35) time horizon 
to capture all relevant long-term costs and consequences.
Study Population
Each patient had characteristics created by randomly sampling the 
trial patient-level data by means of a uniform distribution. These char-
acteristics affected their probability of subsequent model events (eg, 
males had a higher cardiovascular disease risk relative to females). 
The model was run with a large number of simulated patients (50 000) 
to account for interpatient variability and to adequately model a rep-
resentative clinical population.
Model Comparators and Costs
After randomization, trial participants booked a primary care appoint-
ment for a BP check and a medication review. GPs were free to make 
management decisions and drug choice in all 3 randomized groups. 
For usual care, GP antihypertensive treatment decisions were based 
on clinic BP readings. All 3 strategies included the cost of baseline 
medication review, subsequent primary care consultations and antihy-
pertensive prescriptions (Table 2).
Patients in the self-monitoring alone group were trained to self-
monitor their own BP by a nurse and asked to post the readings to 
their practice every month. Additional costs included 15 minutes self-
monitoring training, the BP monitor and 2-part copy forms with reply 
paid envelopes (Table 2). Participants in the telemonitoring group were 
trained, again by a nurse, to self-monitor their own BP and to use an 
SMS text-based telemonitoring service, with web-based data entry 
back-up to send the BP readings. Additional costs included for this strat-
egy were 15 minutes self-monitoring training, 25 minutes telemonitor-
ing training, the BP monitor, and telemonitoring server costs (Table 2). 
The telemonitoring system included reminders, warnings in the case of 
very high or very low readings, and a secure website that GPs could 
use to review their patients’ measurements.8 For the self-monitoring and 
telemonitoring groups, the GP was asked to use the self-monitored BP 
readings to guide any antihypertensive treatment decisions.
Costs of modeled cardiovascular events (detailed in the Model 
Structure section), including initial acute care costs and long-term 
care, were obtained from previously published work and standard ref-
erence costs (Table 2). Costs are reported in 2015/2016 prices (the 
trial took place 2014–2016) and inflated where applicable using the 
Hospital and Community Health Services Index.10 Training and e-
quipment, annuitized over 5 years, were included in the self-monitor-
ing and telemonitoring costs.
Model Structure
The patient pathway is shown in Figure 1. All patients started in the 
well/no event health state. Within a 6-month time cycle, a patient had 
a risk of suffering a fatal or nonfatal cardiovascular event or dying 
from other causes. The possible cardiovascular events in the model 
were stable angina, unstable angina, stroke, myocardial infarction, 
and transient ischemic attack. Ten-year cardiovascular risk was cal-
culated for each individual patient, with the distribution of coro-
nary heart disease and stroke events dependent on age and sex.11,12 
Patients who suffered a nonfatal cardiovascular event transitioned to 
a postevent cardiovascular health state and additional clinical events 
were not modeled. Once a cardiovascular event had occurred, mor-
tality risk was adjusted accordingly. The impact of each interven-
tion in terms of event reduction was applied as a relative risk, taking 
into account the mean differences in systolic BP observed in the 
TASMINH4 trial. Compared with usual care, the mean differences 
Figure 1. Model patient pathways. CHD indicates 
coronary heart disease; CVD, cardiovascular disease; 
MI, myocardial infarction; and TIA, transient ischemic 
attack.
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(at 6 and 12 months, respectively) were −2.1 and −3.5 mm Hg for 
self-monitoring alone and −3.7 and −4.7 mm Hg for telemonitor-
ing.2 Individual relative risks were applied, taking into account age, 
sex, and baseline clinic systolic BP. In the base-case analysis, it was 
assumed that the 12-month differences were maintained over the pa-
tient lifetime. Model inputs are detailed in Table 1.
Half-cycle correction was applied to model costs and outcomes. 
Future costs and outcomes were discounted at an annual rate of 
3.5% as recommended by the National Institute of Health and Care 
Excellence.19
Model Outcomes
Health-related quality of life outcomes were modeled in quality-
adjusted life years (QALYs), taking into account both quality of life 
and survival. Utility scores for health states are detailed in Table 2. 
Each patient’s initial quality of life was the overall mean EQ-5D-5L27 
score at baseline taken from the TASMINH4 trial,8 calculated using 
UK tariff values.28 Utility values for cardiovascular events were 
applied multiplicatively to baseline utility scores. Sex-specific life ta-
bles were used to determine the probability of death at different ages, 
with adjustment to avoid double counting of circulatory deaths.13,14
Analysis
A cost-utility analysis from an NHS/Personal Social Services perspec-
tive was undertaken to estimate Incremental Cost-Effectiveness Ratios 
(ICERs). An ICER was calculated as the difference in costs divided 
by the difference in QALYs of 2 strategies, with results presented 
as cost per QALY gained. The cost-effectiveness of an intervention 
was considered in relation to the lower National Institute of Health 
and Care Excellence threshold of £20 000 per QALY gained.29 In line 
with convention, strategies were ordered from least to greatest cost, 
with each strategy compared against the next more costly strategy, 
and strategies which were dominated or extendedly dominated sub-
sequently excluded.30 Probabilistic Sensitivity Analysis (PSA) was 
undertaken to assess parameter uncertainty.31 Where possible, distri-
butions were attached to probabilities, utilities, and costs in the model. 
Beta distributions were attached to probabilities and utilities, and 
gamma distributions were attached to costs. Log-normal distributions 
were used for the relative risks associated with BP reduction from the 
interventions and relative risks for mortality. The model was run for 
10 000 iterations across 1000 patients, and the results are expressed 
as a Cost-Effectiveness Acceptability Curve.32 The Cost-Effectiveness 
Acceptability Curve shows graphically the probability of cost-effec-
tiveness for all strategies across a range of cost per QALY thresholds.
Deterministic Sensitivity Analyses
The impact of changing model assumptions was undertaken using 
deterministic sensitivity analysis to assess model robustness.31 The 
following scenarios were explored:
1. The time horizon was varied from a lifetime time horizon to 
between 5 and 20 years following the end of the trial.
2. The duration of the impact of BP reduction because of self-
monitoring alone and self-monitoring plus telemonitoring was 
varied from the base-case assumption of lifetime impact.
Table 1. Model Parameters
Parameter Model Estimate Source
Systolic BP reduction (mm Hg) at 6 mo compared with usual care TASMINH4 trial8
  Self-monitoring −2.1 (95% CI, −4.3 to 0.1)  
  Telemonitoring −3.7 (95% CI, −5.9 to −1.5)  
Systolic BP reduction (mm Hg) at 12 mo compared with usual care TASMINH4 trial8
  Self-monitoring −3.5 (95% CI, −5.8 to −1.2)  
  Telemonitoring −4.7 (95% CI, −7.0 to −2.4)  
Mortality and risk of cardiovascular disease
  Probability of noncardiovascular death Age and sex dependent England and Wales 2013–2015 lifetables without circulatory 
death13,14
  Probability of coronary heart disease event 
within 10 y*
Age and sex dependent Calculated with Framingham coronary heart disease and 
stroke risk equations11 and TASMINH4 trial8
  Probability of stroke event within 10 y* Age and sex dependent As above
  Coronary heart disease event distribution 
(age and sex dependent)
MI, 14.3%–37.8%; unstable angina, 10.4%–
20.9%; stable angina, 37.7%–62.9%; and 
coronary heart disease death, 6.6%–17.8%
Ward et al12
  Stroke event distribution (age and sex 
dependent)
Stroke, 51.7%–70.1%; TIA, 13.4%–36.1%; and 
stroke death, 12.2%–16.5%
Ward et al12
  Relative risk of coronary heart events on 
treatment
0.323–0.857 (age and sex dependent) Calculated with meta-analysis by Law and colleagues2 and 
distribution of people on 1–3 drugs in the TASMINH4 trial8
  Relative risk of stroke events on treatment 0.198–0.857 (age and sex dependent) As above
  SMR after myocardial infarction 2.68 (95% CI, 2.48 to 2.91) Brønnum-Hansen and colleagues15
  SMR after unstable angina 2.19 (95% CI, 2.05 to 2.33) NICE guidelines16
  SMR after stable angina 1.95 (95% CI, 1.65 to 2.31) Rosengren and colleagues17
  SMR after stroke 2.72 (95% CI, 2.59 to 2.85) Brønnum-Hansen and colleagues15
  SMR after TIA 1.40 (95% CI, 1.10 to 1.80) Oxfordshire Community Stroke Project18
BP indicates blood pressure; MI, myocardial infarction; NICE, National Institute for Health and Care Excellence; SMR, standardized mortality rate; TASMINH4, 
telemonitoring and/or self-monitoring of blood pressure in hypertension trial; and TIA, transient ischemic attack.
*Left ventricular hypertrophy risk input value for Framingham Equation assumed to be 0%.
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Post hoc, a further 2 sensitivity analyses were undertaken given un-
certainty shown by the PSA as to which option was most cost-ef-
fective. These analyses were designed to investigate the effect of 
bringing the cost of the 2 interventions closer to assess the influence 
of this on ICER given that:
1. Additional administrative work not captured in the clinical record 
was likely to have been an issue for self-monitoring alone from our 
linked qualitative work (Sabrina Grant, personal communication, 
2018). This is because someone had to deal with the paper self-
monitoring records, add the data onto the clinical record system, 
and work out an average BP. As the exact time taken for this task 
was unknown, alternative scenarios for self-monitoring were as-
sessed by including the assumed cost of a GP receptionist’s time 
for data entry in the self-monitoring group using 2 different time 
durations (5 or 10 minutes per month per patient receptionist time).
2. A national rollout of telemonitoring was considered likely to 
lead to reductions in the cost of telemonitoring from economies 
of scale compared with the relatively small scale used in the 
trial. Alternative cost scenarios for telemonitoring were, there-
fore, evaluated by reducing the annual cost of telemonitoring 
by £10 and £20 per year respectively.
Making the telemonitoring more expensive or the self-monitoring less 
expensive were not considered likely enough scenarios to be mod-
eled. Both would have tended to increase the difference between the 
2 interventions in cost and, therefore, favored self-monitoring alone.
Results
Base-case findings are reported in Table 3, ordering strate-
gies from least to greatest cost, with each strategy compared 
against the next more costly strategy. Self-monitoring alone 
was cost-effective compared with usual care, with an ICER 
of £3035 per QALY gained. Telemonitoring resulted in the 
most QALYs and was cost-effective at the £20 000/QALY 
threshold compared with self-monitoring alone, with an ICER 
of £17 424 per QALY. The results of the PSA are shown in 
Figure 2. At a willingness to pay of £20 000 per QALY, tele-
monitoring was the most cost-effective option in 51% of itera-
tions while self-monitoring was the most cost-effective option 
in 38% of iterations. This shows that while self-monitoring 
(with or without telemonitoring) had a high probability of 
being cost-effective, there was high uncertainty as to which 
specific option (telemonitoring or not) was the most cost-ef-
fective compared with usual care.
The results of deterministic sensitivity analysis are shown 
in Table 4. When the model time horizon was reduced to 20, 
10, and 5 years from the end of the trial respectively, the self-
monitoring strategy remained cost-effective compared with 
usual care. The results were also robust when reducing the 
effect of the intervention from lifetime to 10, 5, and 3 years, 
respectively. However, when the effect was assumed to be 
only an additional 2 years, the self-monitoring strategy was no 
longer cost-effective compared with usual care. For all these 
scenarios, telemonitoring was no longer cost-effective com-
pared with self-monitoring alone.
Table 2.  Quality of Life and Costs
Quality of Life Weights Data Source
Utility for initial health state (no events) 0.879 TASMINH4 trial8
Quality of life multipliers   
Stroke 0.629 Ward et al12
Myocardial infarction 0.760 As above
Unstable angina 0.770 As above
Stable angina 0.808 As above
TIA 1 As above
Costs
  Usual care (6 mo) £49 TASMINH4 trial,8 PSSRU 2016 unit costs,10 and British National Formulary18
  Self-monitoring (6 mo) £57 As above
  Self-monitoring plus telemonitoring (6 mo) £71 As above
  Initial stroke costs £8578 Luengo-Fernandez et al20
  Poststroke costs (6 mo) £686 Luengo-Fernandez et al20
  Initial cost of TIA £1141 Diagnostic tests and procedures: Ward et al12;drug costs: relevant NICE 
guidance16,21 and British National Formulary18
  Costs after TIA (6 mo) £36 Relevant NICE guidance16,21 and British National Formulary22
  Initial myocardial infarction costs £5299 Palmer et al23
  Costs after myocardial infarction (6 mo) £469 Taylor et al24
  Initial unstable angina costs £3179 Assumed to be 60% of initial costs of myocardial infarction
  Costs after unstable angina (6 mo) £281 Assumed to be 60% of costs after myocardial infarction
  Initial stable angina cost £420 An outpatient cardiology assessment (service code 320) plus noninvasive 
imaging SPECT scan (service code RA06Z)25
  Costs after stable angina (6 mo) £12 Relevant NICE guidance26 and British National Formulary22
NICE indicates National Institute of Health and Care Excellence; PSSRU, Personal Social Services Research Unit; TASMINH4, telemonitoring and/or self-monitoring of 
blood pressure in hypertension trial; and TIA, transient ischemic attack.
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If an additional 5 minutes of administration time per pa-
tient per month for managing paper results were added to 
self-monitoring, when compared with the base-case results, 
this resulted in a higher ICER for self-monitoring versus 
usual care (£5484/QALY) and a lower ICER for telemoni-
toring (£11 670/QALY) versus self-monitoring. When this 
additional time was increased to 10 minutes per month, 
telemonitoring demonstrated extended dominance over 
self-monitoring alone and had an ICER of £7331/QALY 
compared with usual care. If the cost of telemonitoring 
was reduced annually by £10 per patient, self-monitoring 
remained cost-effective at an ICER of £3305/QALY and the 
ICER for telemonitoring versus self-monitoring reduced to 
£10 554/QALY compared with the base-case result. A de-
crease in the annual cost of telemonitoring by £20 per pa-
tient resulted in a much lower ICER of £3685/QALY when 
compared with self-monitoring.
Discussion
Main Findings
This model-based economic evaluation has demonstrated 
that antihypertensive titration by physicians in primary care 
using patient self-monitoring of BP data is cost-effective 
compared with usual care, provided that the BP improve-
ments associated with self-monitoring observed here last at 
least 3 years after the end of the trial (which lasted 1 year). 
With longtime horizons and the assumption of ongoing ef-
ficacy, telemonitoring was cost-effective over and above 
self-monitoring alone at the lower National Institute of 
Health and Care Excellence threshold of £20 000 per QALY. 
However, this was not the case with shorter durations of 
action or shorter time horizons, although the results were 
finally balanced and sensitive to small increases in costs 
for self-monitoring (5–10 minutes extra work per month 
per person) or small reductions in costs for telemonitoring 
(£10–20 per patient per year), both of which seem plausible. 
PSA reflected these issues and indicated high levels of un-
certainty as to whether self-monitoring alone or in addition 
to telemonitoring was the most cost-effective.
Strengths and Weaknesses
The model was based on the results of TASMINH4, the only 
primary care trial of physician antihypertensive titration utiliz-
ing self-monitoring and/or telemonitoring BP measurements, 
with currently recommended targets for self-monitored BP.33 
Furthermore, patients in the study were drawn from a wide 
range of primary care practices in varied settings across 
England, and therefore, the results are likely to be generaliz-
able, at least in a UK NHS context. Patients in the trial were 
recruited on the basis of standardized clinic BP measure-
ments which might have reduced the white coat effect; how-
ever, this would tend to suggest that self-monitoring might be 
even more cost-effective in a population chosen on the basis 
of normal clinic measurement where the prevalence of white 
coat hypertension might be higher. Furthermore, although 
alternative model parameter estimates would be required to 
produce precise country-specific cost-effectiveness estimates, 
systematic reviews suggest similar effect sizes in self-moni-
toring trials with cointerventions in the UK and internation-
ally.34 Therefore, given that self-monitoring reduced health 
service costs, and these are generally lower in the NHS than 
in other comparable developed countries, these results retain 
wide relevance.
The economic analysis used a patient-level Markov 
simulation35 in assessing the costs and consequences of 
Table 3. Base-Case Results
Strategy Costs Incremental Cost QALYS Incremental QALYs ICER (£/QALY)
Usual care £2706 … 11.0040 … …
Self-monitoring £2829 £124 11.0447 0.0407 £3035
Telemonitoring £3131 £302 11.0621 0.0173 £17 424
Results are per patient and strategies are ordered by ascending costs. ICER indicates incremental cost-effectiveness ratio; and 
QALYs, quality-adjusted life years.
Figure 2. Cost-effectiveness acceptability curve of 
antihypertensive titration options. QALY indicates 
quality-adjusted life year.
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Table 4. Sensitivity Analysis Scenarios
Strategy Costs Incremental Cost QALYS Incremental QALYs ICER (£/QALY)
Base case
  Usual care £2706 … 11.0040 … …
  Self-monitoring £2829 £124 11.0447 0.0407 £3035
  Telemonitoring £3131 £302 11.0621 0.0173 £17 424
20 y time horizon
  Usual care £2264 … 9.6760 … …
  Self-monitoring £2375 £111 9.70280 0.0267 £4161
  Telemonitoring £2646 £271 9.71280 0.0100 £26 933
10 y time horizon
  Usual care £1377 … 6.5648 … …
  Self-monitoring £1463 £85 6.5741 0.0093 £9130
  Telemonitoring £1651 £188 6.5728 0.0040 £46 793
5 y time horizon
  Usual care £743 … 3.8104 … …
  Self-monitoring £796 £53 3.8132 0.0028 £18 709
  Telemonitoring £909 £113 3.8139 0.0006 £179 233
Intervention effectiveness lasts 10 y
  Usual care £2706 … 11.004 … …
  Self-monitoring £2854 £148 11.036 0.032 £4652
  Telemonitoring £3167 £313 11.047 0.011 £28 863
Intervention effectiveness lasts 5 y
  Usual care £2706 … 11.0040 … …
  Self-monitoring £2868 £162 11.0234 0.0193 £8378
  Telemonitoring £3186 £318 11.0315 0.0081 £39 192
Intervention effectiveness lasts 3 y
  Usual care £2706 … 11.0040 … …
  Self-monitoring £2876 £171 11.0158 0.0117 £14 528
  Telemonitoring £3199 £322 11.0193 0.0035 £92 182
Intervention effectiveness lasts 2 y
  Usual care £2706 … 11.0040 … …
  Self-monitoring £2878 £172 11.0120 0.0080 £21 484
  Telemonitoring £3200 £322 11.0153 0.0032 £99 322
Self-monitoring data entry admin work included in cost (£8.40/h×5 min every month per SM patient)
  Usual care £2706  11.0040   
  Self-monitoring £2929 £223 11.0447 0.0407 £5484
  Telemonitoring £3131 £202 11.0621 0.0173 £11 670
Self-monitoring data entry admin work included in cost (£8.40/h×10 min every month per SM patient)
  Usual care £2706 £0 11.0040  …
  Self-monitoring £3029 £323 11.0447 0.0407 Extended domination by 
telemonitoring strategy
  Telemonitoring (compared with usual care) £3131 £425 11.0621 0.0580 £7331
12 mo telemonitoring costs reduced by £10
  Usual care £2706 £0 11.0040   
(Continued )
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the interventions. This is preferable to the more common 
Markov cohort model, which is limited by the use of a pop-
ulation with a homogenous set of characteristics, because 
of the model’s inherent lack of memory.35 The patient-level 
simulation was able to draw on individual patients’ trial data, 
with characteristics allowed to vary (using tracker variables 
to overcome the lack of Markov memory issues), and there-
fore, made the findings representative of the TASMINH4 
trial population. The modeling method was also more ef-
ficient by avoiding the construction of a large number of 
Markov health states.
The base-case model assumed extrapolation of the effec-
tiveness of the interventions beyond the 12 months of the trial 
to a lifetime effect. However, sensitivity analyses demonstrated 
that as long as the intervention effects persisted for an addi-
tional 3 years, self-monitoring would still be cost-effective. 
This seems a reasonable assumption, as the BP differences be-
tween the 2 intervention groups and the usual care group wid-
ened between 6 months and 1 year in the TASMINH4 trial8 
and similarly in other self-monitoring trials.36,37 Undertaking 
the analysis from an NHS/Personal Social Services perspec-
tive, in line with the National Institute of Health and Care 
Excellence reference case, may mean that broader health 
service and societal benefits of telemonitoring have been 
neglected.19 In the future, telemonitoring has the potential 
to be integrated into electronic health care records, allow-
ing seamless management by primary care nurses and GPs, 
and also facilitating remote access to a doctor. Furthermore, 
self-monitoring may be more beneficial to individuals in both 
working age populations and those requiring a carer, reducing, 
for example, time off work to attend appointments either for 
oneself or a relative. Conversely, in the current analysis, any 
additional time required by GPs to process the results from 
self-monitoring or telemonitoring was not captured. The sen-
sitivity analyses showed that inclusion of unrecorded costs of 
processing manual self-monitoring records, or economies of 
scale resulting in cheaper telemonitoring, would make tele-
monitoring more cost-effective. Results of the PSA illustrated 
the considerable uncertainty in the results with similar prob-
abilities of cost-effectiveness for both interventions, in part, 
driven by the uncertainty in the estimates of BP lowering. 
Finally, the risk of further events once someone had an initial 
cardiovascular event was not modeled, and baseline cardio-
vascular disease (affecting around 5% of participants) was not 
included in the model, hence potential additional benefits of 
secondary preventative treatment, which might be expected to 
favor self-monitoring, were ignored.
Findings in the Context of Existing Literature
A previous United Kingdom-based economic evaluation un-
dertook a cost-effectiveness analysis of a trial of 6 months of 
telemonitoring versus usual care.38 However, it was a within-
trial analysis reporting results in natural units (cost per 1 
mm Hg systolic BP point reduced) and did not undertake any 
longer-term modeling of costs and consequences (including 
QALYs) arising from the intervention. Direct comparison of 
within-trial results at 6 months shows that compared with their 
published ICER of £25.60/mm Hg, both self-monitoring and 
telemonitoring in TASMINH4 were much more cost-effective 
compared with usual care (£3.81/mm Hg and £5.95/mm Hg, 
respectively).
Maciejewski et al37 conducted a follow-up analysis of 
their 18-month long United States-based trial which included 
telemedicine and home BP monitoring to assess longer-term 
clinical and economic outcomes. Results showed that the BP 
improvements in the trial were maintained for at least a fur-
ther 18 months after trial completion (because of worsening 
control in the usual care arm), but that health care costs did 
not decrease. Similar results have been recently published 
from a self-monitoring/community pharmacist intervention.36 
Therefore, the extrapolation of the TASMINH4 results over a 
numbers of years seems to be reasonable.
A previous trial by our group (TASMINH2)5 in a sim-
ilar patient population found that self-management with tele-
monitoring and self-titration was cost-effective compared 
with usual care (ICER £1624 per QALY for men and £4923 
for women), which is in accordance with the current find-
ings that telemonitoring was cost-effective when compared 
to usual care.
Implications for Clinical Practice
The TASMINH4 trial demonstrated that self-monitoring, with 
or without telemonitoring, led to significantly lower BP com-
pared with usual care.8 The case for self-monitoring of hy-
pertension (with or without telemonitoring) has been further 
supported by this cost-effectiveness analysis but, ultimately, 
the decision whether or not to implement telemonitoring in 
primary care for the management of hypertension may need 
to include factors such as practice logistics and patient prefer-
ences not included in this modeling exercise, as well as a care-
ful focus on procurement prices.
Perspectives
Antihypertensive titration by physicians in primary care 
using self-monitoring of BP, with or without telemonitoring, 
  Self-monitoring £2829 £124 11.0447 0.0407 £3035
  Telemonitoring £3012 £183 11.0621 0.0173 £10 554
12 mo Telemonitoring costs reduced by £20
  Usual care £2706 £0 11.0040   
  Self-monitoring £2829 £124 11.0447 0.0407 £3035
  Telemonitoring £2893 £64 11.0621 0.0173 £3685
Results are per patient and strategies are ordered by ascending costs. ICER indicates Incremental Cost-Effectiveness Ratio; and QALYs, quality-adjusted life years.
Table 4. Continued
Strategy Costs Incremental Cost QALYS Incremental QALYs ICER (£/QALY)
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is cost-effective compared with usual care, provided self-
monitoring has ongoing effects on BP reduction for at least 
3 additional years. The decision as to whether or not to use 
telemonitoring is finely balanced. However, both digital and 
manual approaches to implementation of self-monitoring are 
cost-effective relative to usual care, so availability of both may 
be appropriate where patient choice determines which is used.
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What Is New?
•	Self-monitoring of blood pressure is increasingly utilized in both primary 
care and specialized clinic settings, but no previous study has assessed 
cost-effectiveness.
•	This study used a modeling approach to consider the long-term cost-ef-
fectiveness of using self-monitoring of blood pressure (with or without 
telemonitoring) to guide treatment decisions by primary care physicians 
for patients with hypertension.
What Is Relevant?
•	Using self-monitoring of blood pressure to guide treatment decisions is 
cost-effective compared with usual care, however, there is uncertainty 
whether self-monitoring is most cost-effective when used alone or when 
combined with telemonitoring.
Summary
Economic modeling suggests that antihypertensive titration by 
physicians in primary care using self-monitoring of blood pressure 
(with or without telemonitoring) would be cost-effective compared 
with usual care. Healthcare organizations/payees should be en-
couraged to implement self-monitoring of blood pressure into u-
sual hypertension care.
Novelty and Significance
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